Skip to main content
Premium Trial:

Request an Annual Quote

Exact Sciences Riskguard Hereditary Cancer Test

Exact Sciences has launched its Riskguard hereditary cancer test in the US. A multi-gene assay, Riskguard uses a blood or saliva sample and provides an individualized patient report that includes gene-specific and familial risks for10 common cancers, including colorectal, breast, prostate, skin, ovarian, endometrial, pancreatic, gastric, kidney and endocrine tumors.

For patients already diagnosed with cancer, knowing about certain gene variants can help create personalized treatment plans for patients, Exact said. Riskguard also helps inform risk stratification for patients who have a family history of cancer by identifying changes in cancer-associated genes, the company added. The assay is covered by Medicare and by some private payors.

The laboratory-developed test is performed in Marshfield, Wisconsin, in the CAP-accredited, CLIA-certified laboratories of PreventionGenetics, a wholly owned subsidiary of Exact Sciences. PreventionGenetics.